Spinal Muscular Atrophy Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Scholar Rock, Biogen, Alcyone, NMD Pharma, Amniotics, Exicure, Aurimed, Astellas, Amylon Therapeutics, AndroScience

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 18+ key pharma and biotech companies are working on 20+ pipeline drugs in the Spinal Muscular Atrophy therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Spinal Muscular Atrophy Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Spinal Muscular Atrophy Therapeutics Market.

The report provides a detailed description of the Spinal Muscular Atrophy drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Spinal Muscular Atrophy Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Spinal Muscular Atrophy Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Spinal Muscular Atrophy therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Muscular Atrophy treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Spinal Muscular Atrophy drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Spinal Muscular Atrophy treatment market.

Learn More about the Clinical and Commercial Development Activities in the Spinal Muscular Atrophy Therapeutics Domain:
https://www.delveinsight.com/report-store/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Spinal Muscular Atrophy Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Spinal muscular atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Request for Sample PDF to Understand More About the Spinal Muscular Atrophy Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Spinal Muscular Atrophy Therapeutics Analysis
There are approx. 18+ key companies developing therapies for Spinal muscular atrophy. Currently, Scholar Rock is leading the therapeutics market with its Spinal muscular atrophy drug candidates in the most advanced stage of clinical development.

Spinal Muscular Atrophy Companies in the Therapeutics Market Include:
• Scholar Rock
• Biogen
• Astellas Pharma
• Alcyone Therapeutics
• AndroScience Corporation
• Hanugen Therapeutics
• Voyager Therapeutics
• Hoffmann-La Roche
• Catalyst Pharmaceuticals
• NMD Pharma
• Biohaven Pharmaceuticals
• CANbridge Pharmaceuticals Inc.
• Aurimed Pharma
• Exicure
• Amylon Therapeutics
• Amniotics
And Many Others

Emerging and Marketed Spinal Muscular Atrophy Therapies Covered in the Report Include:
• Apitegromab: Scholar Rock
• ACTX-401: Alcyone Therapeutics
And Many More

Get an in-depth Assessment of the Emerging Therapies and Spinal Muscular Atrophy Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Spinal Muscular Atrophy Current Treatment Patterns
4. Spinal Muscular Atrophy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Spinal Muscular Atrophy Late-Stage Products (Phase-III)
7. Spinal Muscular Atrophy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Spinal Muscular Atrophy Discontinued Products
13. Spinal Muscular Atrophy Product Profiles
14. Spinal Muscular Atrophy Companies
15. Spinal Muscular Atrophy Drugs
16. Dormant and Discontinued Products
17. Spinal Muscular Atrophy Unmet Needs
18. Spinal Muscular Atrophy Future Perspectives
19. Spinal Muscular Atrophy Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.